The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment.

Mandard, Stéphane; Zandbergen, Fokko; Tan, Nguan Soon; Escher, Pascal; Patsouris, David; Koenig, Wolfgang; Kleemann, Robert; Bakker, Arjen; Veenman, Frank; Wahli, Walter; Müller, Michael; Kersten, Sander (2004). The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. Journal of biological chemistry, 279(33), pp. 34411-34420. American Society for Biochemistry and Molecular Biology 10.1074/jbc.M403058200

[img] Text
J. Biol. Chem.-2004-Mandard-34411-20.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (547kB) | Request a copy

The fasting-induced adipose factor (FIAF, ANGPTL4, PGAR, HFARP) was previously identified as a novel adipocytokine that was up-regulated by fasting, by peroxisome proliferator-activated receptor agonists, and by hypoxia. To further characterize FIAF, we studied regulation of FIAF mRNA and protein in liver and adipose cell lines as well as in human and mouse plasma. Expression of FIAF mRNA was up-regulated by peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARbeta/delta agonists in rat and human hepatoma cell lines and by PPARgamma and PPARbeta/delta agonists in mouse and human adipocytes. Transactivation, chromatin immunoprecipitation, and gel shift experiments identified a functional PPAR response element within intron 3 of the FIAF gene. At the protein level, in human and mouse blood plasma, FIAF was found to be present both as the native protein and in a truncated form. Differentiation of mouse 3T3-L1 adipocytes was associated with the production of truncated FIAF, whereas in human white adipose tissue and SGBS adipocytes, only native FIAF could be detected. Interestingly, truncated FIAF was produced by human liver. Treatment with fenofibrate, a potent PPARalpha agonist, markedly increased plasma levels of truncated FIAF, but not native FIAF, in humans. Levels of both truncated and native FIAF showed marked interindividual variation but were not associated with body mass index and were not influenced by prolonged semistarvation. Together, these data suggest that FIAF, similar to other adipocytokines such as adiponectin, may partially exert its function via a truncated form.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Escher, Pascal

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0021-9258

Publisher:

American Society for Biochemistry and Molecular Biology

Language:

English

Submitter:

PD Dr. Pascal Escher

Date Deposited:

11 Jul 2017 07:34

Last Modified:

31 Jul 2017 08:31

Publisher DOI:

10.1074/jbc.M403058200

PubMed ID:

15190076

BORIS DOI:

10.7892/boris.101769

URI:

https://boris.unibe.ch/id/eprint/101769

Actions (login required)

Edit item Edit item
Provide Feedback